BioVersys AG, a clinical-stage biopharmaceutical company based in Basel, Switzerland, announced on October 20, 2026, the publication of two Phase 1 clinical pharmacology studies of its lead asset BV100 in two leading peer-reviewed antimicrobial journals. The data, published in the International Journal of Antimicrobial Agents and the Journal of Antimicrobial Chemotherapy, provide critical pharmacological support for BV100's use in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC), a pathogen with limited treatment options and mortality rates of up to 50%.
The first paper, published in the International Journal of Antimicrobial Agents, details a lung penetration study in 36 healthy male participants who received intravenous BV100 (rifabutin) 300 mg every 12 hours for four days. Results showed that rifabutin concentrations in lung fluid and alveolar macrophages exceeded plasma concentrations at every time point, with median penetration ratios of approximately 35-fold and over 300-fold, respectively. Repeated dosing was well tolerated. The authors conclude that these pulmonary exposures provide a strong pharmacological rationale for further clinical evaluation of BV100 in severe CRAB pneumonia. The study is available via 10.1016/j.ijantimicag.2026.108014.
The second paper, in the Journal of Antimicrobial Chemotherapy, reports two Phase 1 drug-drug interaction studies. BV100 was found to be a mild CYP3A inducer, reducing midazolam exposure by approximately 47%, and a mild substrate for CYP3A inhibitors, with rifabutin exposure increasing 1.3- to 1.7-fold when co-administered with itraconazole. This profile is milder than that of rifampicin, a strong CYP3A inducer, and BV100 was safe and well tolerated. The findings suggest BV100 may be used more easily alongside the many medications given to critically ill patients. The study is available via DOI: 10.1093/jac/dkag317.
Dr. Glenn Dale, Chief Development Officer of BioVersys and co-author of the publications, commented: "These two papers address the questions that matter most for an intravenous antibiotic in critically ill pneumonia patients. BV100 has very good distribution in lung fluid and alveolar macrophages, and its drug-interaction profile is mild and manageable." Dr. Marc Gitzinger, CEO and founder, added: "Carbapenem-resistant Acinetobacter baumannii represents one of the highest medical needs in infectious disease... These data continue to strengthen the growing scientific basis for BV100 therapy in CRABC pneumonia."
Both datasets form part of the clinical pharmacology foundation of RIV-TARGET, the ongoing Phase 3 registrational trial of BV100 in hospital- and ventilator-associated bacterial pneumonia caused by CRABC. Enrollment is ongoing, with topline data anticipated for early 2028. BV100 is also being studied in the Phase 2b RIV-CARE trial in collaboration with ADVANCE-ID. In September 2026, BV100 received Fast Track Designation from the US FDA, under the Qualified Infectious Disease Product (QIDP) designation granted in 2019. The QIDP status makes BV100 eligible for priority FDA review and a five-year extension of market exclusivity upon approval of the first QIDP indication.
The publications matter because CRABC infections are a growing global health threat, with BioVersys estimating that annual cases in hospitals have surpassed one million worldwide. The high mortality rate and limited treatment options underscore the urgent need for new therapies. BV100's novel formulation of rifabutin, which enables targeting of RNA polymerase in Gram-negative bacteria at human-suitable doses, represents a potential breakthrough. The lung penetration data are particularly important for pneumonia, as adequate drug concentrations at the site of infection are crucial for efficacy. The milder drug-interaction profile compared to rifampicin could simplify treatment in critically ill patients who often receive multiple medications. For investors and the industry, these publications strengthen the scientific rationale for BV100 and de-risk the ongoing Phase 3 program, potentially accelerating the path to regulatory approval and commercialization. The original release can be viewed on www.newmediawire.com.
